Mutant V600E BRAF Increases Hypoxia Inducible Factor-1α Expression in Melanoma
暂无分享,去创建一个
M. Herlyn | Hong Yu | Xiaowei Xu | G. Acs | P. Brafford | R. Edwards | Suresh M. Kumar | S. Kazianis | Lianjun Chen | Patricia Brafford
[1] N. Ibrahim,et al. Therapeutic targets in melanoma: MAPKinase pathway , 2006, Current oncology reports.
[2] Jung Hun Song,et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. , 2006, The Journal of clinical endocrinology and metabolism.
[3] Xiaowei Xu,et al. Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells , 2006, Melanoma research.
[4] V. Trovisco,et al. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. , 2006, Human pathology.
[5] F. Lozupone,et al. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma , 2006, Oncogene.
[6] Joseph A Garcia,et al. HIFing the Brakes: Therapeutic Opportunities for Treatment of Human Malignancies , 2006, Science's STKE.
[7] N. Thomas. BRAF somatic mutations in malignant melanoma and melanocytic naevi , 2006, Melanoma research.
[8] Paul A. Khavari,et al. Modelling cancer in human skin tissue , 2006, Nature Reviews Cancer.
[9] M. Baccarini,et al. Essential role of B-Raf in ERK activation during extraembryonic development , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[10] T. Fukushima,et al. Roles of RAS and BRAF mutations in thyroid carcinogenesis. , 2005, Fukushima journal of medical science.
[11] G. Soff,et al. Update on angiogenesis inhibitors. , 2005, Current opinion in oncology.
[12] M. Piepkorn. The Spitz nevus is melanoma. , 2005, The American Journal of dermatopathology.
[13] D. Aust,et al. Mutations of the BRAF gene in ulcerative colitis‐related colorectal carcinoma , 2005 .
[14] A. Harris,et al. HIF-1α Induces Genetic Instability by Transcriptionally Downregulating MutSα Expression , 2005 .
[15] D. Tuveson,et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. , 2005, Cancer research.
[16] D. Elder,et al. Functional erythropoietin autocrine loop in melanoma. , 2005, The American journal of pathology.
[17] L. Bingle,et al. In vitro study of HIF‐1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI‐3K/Akt and MEK1/ERK pathways , 2005, The Journal of pathology.
[18] Mi-Ock Lee,et al. Novel Function of Orphan Nuclear Receptor Nur77 in Stabilizing Hypoxia-inducible Factor-1α* , 2004, Journal of Biological Chemistry.
[19] Jung Weon Lee,et al. Ras-dependent induction of HIF-1α785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion , 2004, Oncogene.
[20] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[21] D. Morton,et al. Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas , 2004, Clinical Cancer Research.
[22] L. Huang,et al. Phorbol ester stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1alpha isoform: implications for tumor promotion. , 2003, Cancer research.
[23] G. Powis,et al. Hypoxia inducible factor as a cancer drug target. , 2003, Current cancer drug targets.
[24] D. Tuveson,et al. Suppression of BRAF(V599E) in human melanoma abrogates transformation. , 2003, Cancer research.
[25] C. Pritchard,et al. Raf proteins and cancer: B-Raf is identified as a mutational target. , 2003, Biochimica et biophysica acta.
[26] J. McCubrey,et al. BAY-43-9006 Bayer/Onyx. , 2003, Current opinion in investigational drugs.
[27] Manfred Kunz,et al. Molecular responses to hypoxia in tumor cells , 2003, Molecular Cancer.
[28] D. Elder,et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. , 2003, Cancer research.
[29] P. Ratcliffe,et al. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. , 2003, Seminars in cancer biology.
[30] P. Maxwell. Oxygen homeostasis and cancer: insights from a rare disease. , 2002, Clinical medicine.
[31] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[32] C. Peyssonnaux,et al. The Raf/MEK/ERK pathway: new concepts of activation , 2001, Biology of the cell.
[33] L. Poellinger,et al. Mechanism of regulation of the hypoxia‐inducible factor‐1α by the von Hippel‐Lindau tumor suppressor protein , 2000, The EMBO journal.
[34] U. Rapp,et al. Isotype-specific functions of Raf kinases. , 1999, Experimental cell research.
[35] Jessica Lo,et al. HIF‐1α is required for solid tumor formation and embryonic vascularization , 1998 .
[36] U. Rapp,et al. Endothelial apoptosis in Braf-deficient mice , 1997, Nature Genetics.
[37] G. Semenza,et al. Purification and Characterization of Hypoxia-inducible Factor 1 (*) , 1995, The Journal of Biological Chemistry.
[38] G. Johnson,et al. MEK-1 phosphorylation by MEK kinase, Raf, and mitogen-activated protein kinase: analysis of phosphopeptides and regulation of activity. , 1994, Molecular biology of the cell.
[39] E. Keshet,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.
[40] J. Haddad. Oxygen-sensitive pro-inflammatory cytokines, apoptosis signaling and redox-responsive transcription factors in development and pathophysiology. , 2002, Cytokines, cellular & molecular therapy.